

# FDA adds medication adherence indication to Proteus Digital Health's pill sensor

JULY 2, 2015 BY [BRAD PERRIELLO](#) [LEAVE A COMMENT](#)



**Proteus Digital Health** today said the FDA expanded the indications for use for its sensor-enabled pill technology, claiming it as the only FDA-approved device designed to measure medication adherence.

"We are delighted that our collaborative work with the FDA continues to enable positive progress," co-founder & chief medical officer Dr. George Savage said in prepared remarks. "We believe that ingestible devices have the potential to speed clinical trials and improve the real-world effectiveness of medicines in community settings."

Redwood Shores, Calif.-based Proteus **said** its ingestible sensor logs actual intake time as a quantifiable event, communicating with an adhesive patch worn on the torso.

A year ago **Proteus drummed up a \$172 million Series G round**. Although the company didn't provide details on that funding, previous backers include **Medtronic** (NYSE:MDT), **Novartis** (NYSE:NVS), Kaiser Permanente and others.